Prognosis
Investors Brace for Barrage of Covid Vaccine Data to Roil Market
- Pfizer and BioNTech’s vaccines are due in a few weeks
- Options market shows expectation for gains in Moderna, Pfizer
Photographer: Wang Zhao/AFP via Getty Images
This article is for subscribers only.
The next month or two has the potential to wreak havoc in the health-care sector and the market as a barrage of Covid-19 vaccine test results roll in at the tail end of the U.S. presidential election.
“The vaccine outlook will ultimately dwarf the election in terms of market impact,” Goldman Sachs’s strategists said. An earlier-than-expected vaccine would send equity values higher while a delay could send the market lower no matter what the election’s outcome, the bank’s analysis shows.